Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus TROSPIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus TROSPIUM CHLORIDE.
DETROL LA vs TROSPIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Tropium chloride is a quaternary ammonium compound that acts as a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3), thereby reducing smooth muscle tone in the bladder, decreasing detrusor overactivity, and increasing bladder capacity.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
20 mg orally twice daily, extended-release 60 mg orally once daily in the morning.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Terminal elimination half-life: 10-20 hours (mean 14 hours); clinical context: supports twice-daily dosing
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Renal: 65% (40% unchanged, 25% as metabolites); Fecal/Biliary: 35% (primarily via bile)
Category C
Category A/B
Anticholinergic
Anticholinergic